Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating ELV001 as an add-on therapy for adults with active rheumatoid arthritis who have not responded adequately to methotrexate and tumor necrosis factor inhibitors. This Phase 2 randomized, double-blind, placebo-controlled study aims to assess the safety and effectiveness of different doses of ELV001. Approximately 180 to 220 participants aged 18 to 75 years will be enrolled. Participants will be assigned to one of four groups placebo, ELV001 25 mg, 75 mg, or 125 mg daily. The study includes a 4-week screening period, a 12-week double-blind placebo-controlled treatment phase, followed by a 12-week extension where some participants receive higher doses of ELV001. A 4-week safety follow-up concludes the 32-week study. During the study, participants will undergo regular assessments including disease activity scoring, joint counts, blood tests, vital signs, electrocardiograms, and questionnaires about health and function. Researchers will monitor adverse events and drug levels in the blood. The main outcome measured is the change in disease activity score from baseline to week 12. Safety and efficacy will be tracked through week 28, with total participation lasting up to 32 weeks.
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD1163, a novel bispecific antibody, in adults with moderately-to-severely active rheumatoid arthritis RA. AZD1163 targets enzymes involved in protein citrullination, which leads to the production of harmful antibodies in RA. This Phase II, randomized, double-blind, placebo-controlled study focuses on adults with positive anti-citrullinated peptide antibodies ACPA who are already receiving standard treatments. Participants will be randomly assigned to one of four groups to receive subcutaneous injections of either one of three doses of AZD1163 or a placebo, all combined with their standard care including conventional synthetic disease-modifying antirheumatic drugs csDMARDs or tumor necrosis factor inhibitors TNFi with or without csDMARDs. The treatment period lasts 24 weeks, followed by a safety follow-up phase of 28 weeks. During the study, participants will undergo assessments including measures of disease activity using scores such as DAS28-CRP at 12 weeks. Additional evaluations will monitor response criteria, clinical disease activity indices, and the pharmacokinetics and immunogenicity of AZD1163 up to 24 weeks and during follow-up. Safety and efficacy will be closely monitored throughout the treatment and follow-up periods, with total participation lasting approximately 52 weeks.